Although it is known that molecules with anti-HIV activity circulate in human blood, their identification has been hampered by difficulties in the purification and characterization of such compounds.

These include two antibodies that thwart more than 90 percent of circulating HIV-1 strains, a discovery that may aid in the development of a vaccine. VRC01 (green and blue) binding to the gp120 ...